Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
05 nov. 2024 08h30 HE
|
Inozyme Pharma Inc.
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric...
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
06 août 2024 08h30 HE
|
Inozyme Pharma Inc.
Inozyme reported financial results for the second quarter ended June 30, 2024, and provided business highlights.
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
07 mai 2024 08h30 HE
|
Inozyme Pharma Inc.
Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights.
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
26 mars 2024 08h30 HE
|
Inozyme Pharma Inc.
Inozyme announced that it will host a conference call and webcast on Monday, Apr. 8, 2024 at 8:00 a.m. ET.
Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer
04 févr. 2021 06h00 HE
|
Inozyme Pharma Inc.
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal...
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
04 janv. 2021 06h00 HE
|
Inozyme Pharma Inc.
– U.S. Food and Drug Administration cleared Investigational New Drug Application – – United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application – –...
Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
12 nov. 2020 06h00 HE
|
Inozyme Pharma Inc.
– Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency – – Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment...
Inozyme Pharma Appoints Kevin B. Johnson, Ph.D., MBA, as Senior Vice President, Regulatory Affairs
09 nov. 2020 06h00 HE
|
Inozyme Pharma Inc.
BOSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal...